After Forming H&S, Is Ironwood Pharmaceuticals, Inc. (IRWD)’s Near-Term Analysis Negative?

September 16, 2018 - By Dolores Ford

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Investors sentiment increased to 1.03 in Q2 2018. Its up 0.33, from 0.7 in 2018Q1. It is positive, as 19 investors sold Ironwood Pharmaceuticals, Inc. shares while 43 reduced holdings. 22 funds opened positions while 42 raised stakes. 146.28 million shares or 2.74% less from 150.40 million shares in 2018Q1 were reported.
Sarissa Cap Mngmt Lp holds 12.91% or 3.37 million shares in its portfolio. Los Angeles Cap Management And Equity Inc invested in 0% or 16,315 shares. Parametric Port Associate Lc has 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 82,448 shares. Amalgamated Commercial Bank has invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Great West Life Assurance Can reported 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). The California-based California Public Employees Retirement has invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Quantbot Tech Limited Partnership reported 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Piedmont Invest Advsrs Ltd stated it has 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). State Of Wisconsin Inv Board accumulated 435,030 shares or 0.02% of the stock. Bnp Paribas Arbitrage invested in 0% or 7,245 shares. Geode Capital Ltd Liability Corporation holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 1.42M shares. California State Teachers Retirement Sys invested in 212,015 shares. Bankshares Of Montreal Can holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 5,027 shares. Moreover, Swiss National Bank & Trust has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 238,300 shares. Wells Fargo And Company Mn invested in 0% or 91,021 shares.

Since June 5, 2018, it had 0 insider purchases, and 9 insider sales for $4.91 million activity. Another trade for 29,551 shares valued at $583,632 was sold by Gilbert Halley E. On Wednesday, August 22 the insider Currie Mark G sold $2.40M. McHugh Julie had sold 1,500 shares worth $26,430. 188 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares with value of $3,423 were sold by Consylman Gina. MCCOURT Thomas A sold $600,000 worth of stock.

The stock of Ironwood Pharmaceuticals, Inc. (IRWD) formed H&S with $16.81 target or 8.00 % below today’s $18.27 share price. The 5 months Head & Shoulders indicates high risk for the $2.80 billion company. It was reported on Sep, 16 by Faxor.com. If the $16.81 price target is reached, the company will be worth $223.84M less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.44% or $0.08 during the last trading session, reaching $18.27. About 612,412 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 14.01% since September 16, 2017 and is uptrending. It has underperformed by 1.61% the S&P500.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on November, 1. They expect $-0.19 earnings per share, down 5.56 % or $0.01 from last year’s $-0.18 per share. After $-0.28 actual earnings per share reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -32.14 % EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 7 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Ironwood Pharma had 9 analyst reports since April 19, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Wells Fargo on Thursday, May 31. As per Thursday, May 31, the company rating was maintained by Mizuho. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, July 18. Morgan Stanley downgraded the stock to “Underweight” rating in Wednesday, May 9 report. The stock has “Buy” rating by Mizuho on Wednesday, May 2. On Thursday, August 9 the stock rating was maintained by Wells Fargo with “Outperform”. As per Thursday, April 19, the company rating was initiated by Berenberg.

More news for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were recently published by: Bizjournals.com, which released: “Ahead of split, Ironwood gets FDA fast track status for heart drug” on September 13, 2018. Streetinsider.com‘s article titled: “Ironwood Pharma (IRWD) Announces FDA Fast Track Designation for Praliciguat for Heart Failure” and published on September 13, 2018 is yet another important article.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.80 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>